Foreskin keratinocyte (neonatal)

DB10772ApprovedCell transplant therapiesAllogeneic Cultured Cell Scaffold

Foreskin keratinocyte (neonatal) is a treatment of skin cells used to accelerate wound closure and healing. Skin, the largest organ of the human body, plays the main role in protecting the body from mechanical damage.

Mechanism
Curator reviewed · 4 references
Primary indication
For chronic leg ulcers and diabetic foot.Curator reviewed · 1 structured indication
First approval
United States, 2012
Also known as
foreskin keratinocyte, neonatal
Brand names
  • Gintuit

Resolves to

Clinical / RWD

What you can answer from here — as of April 02, 2025

12Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
1Marketed productAcross 1 country and 1 labeller
Sign in
25+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Foreskin keratinocyte (neonatal), and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account